Retatrutide Phase 3 Results: Eli Lilly’s TRIUMPH-1 Trial Explained
Eli Lilly’s latest TRIUMPH-1 Phase 3 data reported major weight-loss outcomes for retatrutide, an investigational triple receptor agonist targeting GIP, GLP-1, and glucagon pathways. This page explains the results in plain English, what they mean for obesity research, and what they do not yet prove.
Direct Answer: What Did the New TRIUMPH-1 Results Show?
Lilly reported that adults with obesity or overweight without diabetes who received retatrutide in TRIUMPH-1 had large average body-weight reductions over 80 weeks. The highest 12 mg dose produced an average 70.3 lb loss, equal to 28.3% of starting body weight. In a 104-week extension subgroup with baseline BMI of at least 35, the 12 mg group reached an average 85.0 lb loss, equal to 30.3% of starting body weight.
Key Takeaways From the TRIUMPH-1 Retatrutide Results
- The headline result was 28.3% average body-weight reduction at 80 weeks with the 12 mg retatrutide group, compared with 2.2% for placebo.
- The 9 mg group also produced a large result: 25.9% average body-weight reduction at 80 weeks.
- The 4 mg group still reached 19.0% average body-weight reduction with fewer dose-escalation steps.
- Nearly half of participants on 12 mg reached at least 30% weight loss, a threshold Lilly described as historically associated with bariatric surgery-level weight reduction.
- Cardiometabolic markers improved, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein.
- The trial does not prove fewer heart attacks, strokes, cancers, or deaths. Those require longer and more specific outcomes trials.
- Retatrutide remains investigational. Lilly’s clinical-trial results do not make it an approved medication.
Plain English Summary
What happened?
Lilly tested retatrutide in a large Phase 3 obesity trial. Participants received weekly retatrutide or placebo. At 80 weeks, the strongest dose group lost far more weight than placebo.
Why does it matter?
The 12 mg group lost an average of more than one-quarter of body weight. In practical terms, a 250 lb starting weight with 28.3% reduction would equal about 71 lb of average weight loss.
Why is retatrutide different?
Retatrutide is designed to activate three receptor pathways: GIP, GLP-1, and glucagon. That is why it is often described as a triple agonist.
What is the caution?
TRIUMPH-1 was not a cancer-prevention trial or a heart-attack outcome trial. The data show major weight loss and improved risk markers, not confirmed reductions in cancer, heart attacks, stroke, or mortality.
Explore Retatrutide From Luxara Labs
Luxara Labs provides retatrutide with a focus on transparent sourcing, published lab results, clear product information, and reliable fulfillment across Canada and the United States.
TRIUMPH-1 Results Table
The table below summarizes Lilly’s reported efficacy-estimand results for TRIUMPH-1 at 80 weeks.
| Group | Average body-weight change at 80 weeks | Average absolute weight change | Achieved at least 25% loss | Achieved at least 30% loss | Achieved at least 35% loss |
|---|---|---|---|---|---|
| Retatrutide 4 mg | -19.0% | -47.2 lb | 27.8% | 15.3% | 5.9% |
| Retatrutide 9 mg | -25.9% | -64.4 lb | 52.9% | 37.9% | 20.8% |
| Retatrutide 12 mg | -28.3% | -70.3 lb | 62.5% | 45.3% | 27.2% |
| Placebo | -2.2% | -5.5 lb | 2.2% | 0.5% | 0.3% |
Source: Eli Lilly and Company TRIUMPH-1 topline Phase 3 release, May 21, 2026.
The 104-Week Extension Result
Lilly also reported a pre-specified blinded extension in participants with a baseline BMI of at least 35 who completed the main 80-week trial and tolerated their assigned medication. In that extension, participants receiving the 12 mg pathway reached an average 30.3% body-weight reduction at 104 weeks.
Why this matters
The extension result suggests that, at least in this subgroup, average weight reduction had not necessarily finished by week 80. For researchers tracking incretin-based obesity pharmacology, this is one of the most important signals in the TRIUMPH-1 release.
How Retatrutide Works: The Triple Agonist Concept
Retatrutide is being studied as a single molecule that activates three hormone receptor pathways: GIP, GLP-1, and glucagon. This makes it different from single-pathway GLP-1 agonists and dual GIP/GLP-1 agonists.
| Pathway | Plain English Role | Why Researchers Care |
|---|---|---|
| GLP-1 | Supports appetite regulation and glucose-related signaling. | Central pathway in the modern incretin-based obesity and metabolic research field. |
| GIP | Involved in insulin and metabolic signaling. | Part of the dual-agonist strategy seen in tirzepatide research. |
| Glucagon | Associated with energy balance, hepatic metabolism, and substrate mobilization. | May help explain why triple agonism is being studied for body-weight reduction and cardiometabolic effects. |
Simple explanation
GLP-1 and GIP are often discussed in relation to appetite and glucose regulation. Glucagon adds another metabolic pathway. Retatrutide’s research interest comes from combining all three signals into one investigational molecule.
Cardiometabolic Findings: What Improved?
Lilly reported significant improvements from baseline across several cardiovascular and metabolic risk markers. These included waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein.
Improved risk markers
The TRIUMPH-1 release reported improvements in several markers commonly associated with cardiometabolic risk. That is important because obesity research is no longer just about scale weight. It is also about metabolic health signals.
Not the same as outcomes
Better risk markers do not automatically prove fewer heart attacks, fewer strokes, or longer life. Those endpoints require dedicated outcome studies with enough time and enough cardiovascular events to measure the difference.
What TRIUMPH-1 Does Not Prove Yet
Important interpretation
TRIUMPH-1 is highly important obesity research, but it should not be overread. The study was designed around weight reduction and related endpoints. It does not prove that retatrutide directly reduces cancer incidence, prevents heart attacks, prevents strokes, or extends lifespan.
| Question | What TRIUMPH-1 supports | What remains unproven |
|---|---|---|
| Does retatrutide reduce body weight? | Yes, the Phase 3 topline data showed large average weight reductions. | Long-term maintenance patterns still require additional study. |
| Does it improve heart-risk markers? | Yes, Lilly reported improvements in several cardiometabolic markers. | Fewer heart attacks, strokes, and cardiovascular deaths are not proven by this trial. |
| Does it reduce cancer risk? | TRIUMPH-1 does not establish cancer-risk reduction. | Any cancer-risk claim would require specific long-term cancer incidence data. |
| Does it treat diabetes? | TRIUMPH-1 excluded people with diabetes. Lilly separately reported TRANSCEND-T2D-1 data in type 2 diabetes. | TRIUMPH-1 itself should not be used as the main diabetes-efficacy evidence. |
How TRIUMPH-1 Fits With Other Retatrutide Research
TRIUMPH-1 is now one of the most important retatrutide Phase 3 obesity readouts, but it should be understood alongside earlier and parallel research.
| Study or release | Population | Main research relevance |
|---|---|---|
| Phase 2 retatrutide obesity trial | Adults with obesity or overweight without diabetes | Established earlier proof-of-concept for substantial weight reduction over 48 weeks. |
| TRANSCEND-T2D-1 | Adults with type 2 diabetes | Lilly reported A1C reductions and weight loss in a type 2 diabetes population. |
| TRIUMPH-4 | Adults with obesity or overweight and knee osteoarthritis | Lilly reported weight reduction plus improvement in knee pain and physical function measures. |
| TRIUMPH-1 | Adults with obesity or overweight without diabetes | Reported the major 80-week obesity readout with 28.3% average body-weight reduction at 12 mg. |
Research Summary
Retatrutide is an investigational triple hormone receptor agonist being studied by Eli Lilly for obesity and related metabolic conditions. In the May 21, 2026 TRIUMPH-1 Phase 3 topline release, Lilly reported that adults with obesity or overweight without diabetes receiving 12 mg retatrutide lost an average of 70.3 lb, equal to 28.3% of body weight, over 80 weeks. The 9 mg group lost an average of 25.9%, the 4 mg group lost an average of 19.0%, and placebo lost an average of 2.2%. Lilly also reported that 45.3% of participants receiving 12 mg achieved at least 30% weight loss. In a 104-week extension subgroup with baseline BMI of at least 35, the 12 mg pathway reached an average 30.3% body-weight reduction.
Quality and Transparency
For buyers evaluating peptide suppliers, clinical-trial headlines are only one part of the picture. Product quality, batch traceability, storage practices, COA interpretation, and supplier transparency also matter.
Published Lab Results
Luxara Labs maintains a dedicated lab results resource so buyers can review available testing documentation.
COA Education
Learn how to read a certificate of analysis, including purity, method, batch, and documentation details.
Research Standards
Review Luxara’s research standards, handling guidance, and transparency resources.
FAQ: Retatrutide TRIUMPH-1 Phase 3 Results
What was the newest retatrutide Phase 3 result from Eli Lilly?
Lilly announced TRIUMPH-1 topline Phase 3 results on May 21, 2026. The highest 12 mg retatrutide group lost an average of 70.3 lb, equal to 28.3% of body weight, over 80 weeks.
What is TRIUMPH-1?
TRIUMPH-1 is a Phase 3, randomized, double-blind, placebo-controlled clinical trial studying retatrutide in adults with obesity or overweight and at least one weight-related comorbidity, without diabetes.
How much weight did participants lose on retatrutide?
Lilly reported average body-weight reductions of 19.0% with 4 mg, 25.9% with 9 mg, and 28.3% with 12 mg at 80 weeks, compared with 2.2% for placebo.
Did retatrutide reduce cancer risk in TRIUMPH-1?
No cancer-risk reduction was established in the TRIUMPH-1 topline results. The trial reported weight-loss outcomes and cardiometabolic risk-marker improvements, not long-term cancer incidence outcomes.
Did retatrutide reduce heart attacks or strokes?
TRIUMPH-1 reported improvements in several cardiometabolic markers, but it did not prove reductions in heart attacks, strokes, or cardiovascular death. Those outcomes require dedicated cardiovascular outcome studies.
Is retatrutide approved?
Retatrutide remains an investigational compound. Lilly’s TRIUMPH-1 results are Phase 3 clinical-trial data, but they do not mean the compound is approved for general medical use.
How is retatrutide different from semaglutide or tirzepatide?
Semaglutide is generally discussed as a GLP-1 receptor agonist, tirzepatide as a dual GIP and GLP-1 receptor agonist, and retatrutide as a triple GIP, GLP-1, and glucagon receptor agonist.
Where can readers learn more about retatrutide?
Readers can review the Luxara Labs retatrutide research guide, the Retatrutide vs Tirzepatide comparison, and the GLP-1, GIP and Triple Agonist Peptides overview for more context.
Research References
- Eli Lilly and Company. Retatrutide TRIUMPH-1 Phase 3 obesity trial topline results. May 21, 2026.
- ClinicalTrials.gov. NCT05929066. A Study of Retatrutide in Participants Who Have Obesity or Overweight.
- Eli Lilly and Company. Retatrutide TRIUMPH-4 Phase 3 knee osteoarthritis and obesity trial topline results. December 11, 2025.
- Eli Lilly and Company. Retatrutide TRANSCEND-T2D-1 Phase 3 type 2 diabetes trial topline results. March 19, 2026.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
- PubMed record: Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
- Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials.